Syk抑制剂Entospletinib在完全人源大疱性类天疱疮离体模型中消除表皮-真皮分离
大疱性类天疱疮(BP)缺乏靶向治疗,Syk激酶在免疫应答中起关键作用。本研究在完全人源BP离体模型中测试第二代Syk抑制剂entospletinib,发现其以约16 nM的半数抑制浓度显著减少表皮-真皮分离,并降低粒细胞ROS产生、颗粒释放和铺展,但不影响趋化迁移或存活,提示Syk抑制剂可能对BP有治疗益处。
要点
- Entospletinib在完全人源BP离体模型中显著减少表皮-真皮分离。
- 其半数抑制浓度约为16 nM,并降低粒细胞ROS产生与颗粒释放。
- Entospletinib不影响粒细胞趋化迁移、非生理刺激反应或存活。
核心结论
- Entospletinib可能通过抑制粒细胞对沉积免疫复合物的反应性来消除表皮-真皮分离,Syk抑制剂或对BP有治疗益处。
研究设计与样本
- 在完全人源BP离体模型系统中测试entospletinib的效果:将BP血清处理的人冷冻皮肤切片与正常人粒细胞及新鲜血浆共孵育。
主要发现
- BP血清处理的人冷冻皮肤切片与正常人粒细胞及新鲜血浆共孵育触发的表皮-真皮分离依赖补体、NADPH氧化酶和蛋白酶活性。
- Entospletinib以约16 nM的半数抑制浓度显著减少表皮-真皮分离。
- Entospletinib降低人粒细胞在固定化免疫复合物(通用抗原-抗体对或重组XVII型胶原与BP血清成分)上铺展时的ROS产生、颗粒释放和铺展。
- Entospletinib不影响人粒细胞的趋化迁移、对佛波酯非生理刺激的反应或粒细胞存活。
关键数值与推荐
- Entospletinib减少表皮-真皮分离的半数抑制浓度约为16 nM。
临床怎么用
- Entospletinib或其他Syk抑制剂可能为BP提供治疗获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bullous pemphigoid (BP) is an autoantibody-mediated blistering skin disease characterized by local inflammation and dermal-epidermal separation, with no approved targeted therapy. The Syk tyrosine kinase is critical for various functions of the immune response. Second-generation Syk inhibitors such as entospletinib are currently being tested for hematological malignancies. Our aim was to test the effect of entospletinib in a fully human model system of BP. Incubating BP serum-treated human frozen skin sections with normal human granulocytes and fresh plasma triggered dermal-epidermal separation that was dependent on complement, NADPH oxidase, and protease activity. Entospletinib dramatically reduced dermal-epidermal separation with a half-maximal inhibitory concentration of ≈16 nM. Entospletinib also reduced ROS production, granule release, and spreading of human granulocytes plated on immobilized immune complexes consisting either of a generic antigen-antibody pair or of recombinant collagen type XVII (BPAg2) and BP serum components (supposedly autoantibodies). However, entospletinib did not affect the chemotactic migration of human granulocytes or their responses to nonphysiological stimulation by phorbol esters. Entospletinib had no effect on the survival of granulocytes either. Taken together, entospletinib abrogates dermal-epidermal separation, likely through inhibition of granulocyte responsiveness to deposited immune complexes. Entospletinib or other Syk inhibitors may provide therapeutic benefits in BP.
引用
- Vikár S, Szilveszter KP, Koszorú K, et al. The Syk Inhibitor Entospletinib Abolishes Dermal-Epidermal Separation in a Fully Human Ex Vivo Model of Bullous Pemphigoid. J Invest Dermatol. 2024. PMID: 38296021. doi:10.1016/j.jid.2024.01.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。